BRIEF-Aeterna and Rafa Laboratories sign license agreement for Zoptrex in Israel

Mon Aug 1, 2016 8:43am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 1 (Reuters) - Aeterna Zentaris Inc

* Aeterna Zentaris and Rafa Laboratories sign exclusive license agreement for Zoptrex in Israel

* Company expects to complete phase 3 clinical trial in Q3 of 2016

* Company and Rafa have also entered into a supply agreement

* Entitled to receive a non-refundable upfront payment in consideration for license to Rafa of intellectual property related to Zoptrex

* Company will supply Zoptrex to Rafa for duration of license agreement Source text for Eikon: Further company coverage: